Siemens Fonds Invest GmbH Purchases New Holdings in Organon & Co. (NYSE:OGN)

Siemens Fonds Invest GmbH purchased a new position in shares of Organon & Co. (NYSE:OGN) during the fourth quarter, Holdings Channel reports. The firm purchased 603,115 shares of the company’s stock, valued at approximately $8,998,000.

A number of other hedge funds have also recently added to or reduced their stakes in OGN. Vanguard Group Inc. lifted its position in shares of Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock valued at $453,593,000 after acquiring an additional 218,165 shares during the period. Pacer Advisors Inc. raised its stake in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Organon & Co. by 1.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock valued at $147,634,000 after purchasing an additional 136,760 shares in the last quarter. LSV Asset Management lifted its position in Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock worth $112,274,000 after purchasing an additional 30,557 shares during the period. Finally, Deprince Race & Zollo Inc. grew its stake in Organon & Co. by 7.0% during the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company’s stock worth $70,561,000 after buying an additional 308,267 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Insider Transactions at Organon & Co.

In other news, VP Daniel Karp bought 3,500 shares of the company’s stock in a transaction on Tuesday, May 6th. The stock was purchased at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the completion of the transaction, the vice president now owns 46,669 shares of the company’s stock, valued at $384,552.56. This trade represents a 8.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Matthew M. Walsh purchased 11,400 shares of the business’s stock in a transaction dated Monday, May 5th. The shares were purchased at an average cost of $8.82 per share, for a total transaction of $100,548.00. Following the completion of the purchase, the chief financial officer now directly owns 144,484 shares of the company’s stock, valued at approximately $1,274,348.88. This represents a 8.57% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 102,345 shares of company stock worth $902,430. Corporate insiders own 1.96% of the company’s stock.

Organon & Co. Stock Up 9.6%

Shares of NYSE OGN opened at $8.81 on Friday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 2.65, a PEG ratio of 0.90 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $23.10. The stock has a 50-day moving average price of $12.34 and a two-hundred day moving average price of $14.42.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.13. The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm’s quarterly revenue was down 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.22 EPS. As a group, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be issued a dividend of $0.02 per share. The ex-dividend date is Monday, May 12th. This represents a $0.08 annualized dividend and a dividend yield of 0.91%. Organon & Co.’s dividend payout ratio (DPR) is presently 2.78%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Evercore ISI downgraded shares of Organon & Co. from an “outperform” rating to an “inline” rating in a research report on Friday, May 2nd. Finally, Piper Sandler cut their target price on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.